Traitement médical de la RCH grave: lesquels et jusqu’où?

Severe ulcerative colitis: which drugs and when?

Résumé

Une poussée sévère de rectocolite hémorragique doit être traitée par la colectomie en urgence dans les formes compliquées et par une corticothérapie intraveineuse dans les autres situations. En cas de corticorésistance, la ciclosporine ou l’infliximab peuvent être proposés. La colectomie est recommandée en cas d’échec du traitement de première ou deuxième ligne selon les cas. Les stratégies médicamenteuses de troisième ligne ou les associations d’immunosuppresseurs ne sont ni validées ni recommandées.

Abstract

Severe ulcerative colitis must be treated by emergency colectomy for complicated forms, and with intravenous steroids in other situations. When steroids have failed, ciclosporin or infliximab may be tested. Colectomy is mandatory in case of failure of first or second line therapy. Third line drug strategies or combined immunosuppressive therapies are not recommended.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Goligher JC, de Dombal FT, Graham NG, Watkinson G (1967) Early surgery in the management of severe ulcerative colitis. Br Med J 3: 193–195

    PubMed  CAS  Google Scholar 

  2. 2.

    Kornbluth A, Sachar DB (2004) Ulcerative colitis guidelines in adults (update): American College of Gastroenterology. Practice parameters committee. Am J Gastro 1371–1385

  3. 3.

    Aceituno M, Garcia Planella E, Heredia C, et al. Steroid-refractory Ulcerative Colitis: Predictive Factors of Response to Cyclosporine and Validation in an Independent Cohort. Infl Bowel Dis, sous presse

  4. 4.

    Järnerot G, Hertervig E, Friis-Liby IL, et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis. Randomised placebo controlled study. Gastroenterology 128: 1805–1811

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report of a therapeutic trial. Br Med J 2: 1041–1048

    PubMed  CAS  Article  Google Scholar 

  6. 6.

    Truelove SC, Jewell DP (1974) Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1: 1067–1070

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Truelove SC, Willoughby CP, Lee EG, Kettlewell MGW (1978) Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 2: 1086–1088

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Turner D, Walsh CM, Steinhart AH, Griffiths AM (2007) Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 5: 103–110

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Gustavsson A, Halfvarson J, Magnuson A, et al. (2007) Long term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 102: 2513–2519

    PubMed  Article  Google Scholar 

  10. 10.

    Berghouse LM, Elliott PR, Lennard Jones JE, et al. (1982) Plasma prednisone levels during intravenous therapy in acute colitis. Gut 23: 980–983

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Bossa F, Fiorella S, Caruso N, et al. (2007) Continuous Infusion VersusBolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. Am J Gastroenterol 102: 601–608

    PubMed  Article  Google Scholar 

  12. 12.

    Rosenberg W, Ireland A, Jewell DP (1990) High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 12: 40–41

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Dickinson RJ, O’Connor HJ, Pinder I, et al. (1985) Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26: 1380–1384

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Chapman RW, Selby WS, Jewell DP (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27: 1210–1212

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Mc Intyre PB, Powell-Tuck J, Wood SR, et al. (1986) Controlled trial of bowel rest in the treatment of severe ulcerative colitis. Gut 27: 481–485

    Article  CAS  Google Scholar 

  16. 16.

    Dickinson RJ, Ashton MG, Axon ATR, et al. (1980) Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 79: 1198–1204

    Google Scholar 

  17. 17.

    Lindgren SC, Flood LM, Kilander AF, et al. (1998) Early predictors of glucosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10: 831–835

    PubMed  CAS  Google Scholar 

  18. 18.

    Travis SP, Farrant JM, Ricketts C, et al. (1996) Predicting outcome in ulcerative colitis. Gut 38: 905–910

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Ho GT, Mowat C, Goddard CJR, et al. (2004) Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second line therapy or surgery. Alim Pharmacol Ther 19: 1079–1087

    Article  CAS  Google Scholar 

  20. 20.

    Gargouri D, Carbonnel F, Beaugerie L, et al. (2000) Predictive factors of outcome of intensive intravenous treatment for severe ulcerative colitis. Alim Pharmacol Ther 14: 273–279

    Article  Google Scholar 

  21. 21.

    Honda M, Orii F, Ayabe T, et al. (2000) Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118: 859–866

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Lichtiger S, Present DH, Kornbluth A, et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841–1845

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    D’Haens G, Lemmens L, Hiele L, et al. (2001) Intravenous cyclosporin versus corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120: 1323–1329

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K (2005) Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 1: CD004277

  25. 25.

    Sandborn WJ (1995) A critical review of cyclosporine therapy in inflammatory bowel disease. Infl Bowel Dis 1: 48–63

    Article  Google Scholar 

  26. 26.

    Carbonnel F, Boruchowicz A, Duclos B, et al. (1996) Intravenous cyclosporine in attacks of ulcerative colitis: short term and long term responses. Dig Dis Sci 41: 2471–2476

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Stack WA, Long RG, Hawkey CJ (1998) Short-and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 12: 973–978

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Wenzl HH, Petritsch W, Aichbichler BW, et al. (1998) Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis. Z Gastroenterol 36(4): 287–293

    PubMed  CAS  Google Scholar 

  29. 29.

    Reimund JM, Duclos B, Baumann R (1997) Traitement des formes sévères de rectocolite hémorragique par la cyclosporine. A propos de 7 cas. Ann Med Interne 148: 527–529

    CAS  Google Scholar 

  30. 30.

    Van Gossum A, Schmit A, Adler M, et al. (1997) Short-and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 60: 197–200

    PubMed  Google Scholar 

  31. 31.

    Santos J, Baudet S, Casellas F, et al. (1995) Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 20: 285–289

    PubMed  CAS  Article  Google Scholar 

  32. 32.

    Cohen RD, Stein R, Hanauer SB (1999) Intravenous cyclosporine in ulcerative colitis. A five-year experience. Am J Gastroenterol 94: 1587–1592

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Fernández-Bañares F, Bertrán X, Esteve-Comas M, et al. (1996) Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 91: 2498–2499

    PubMed  Google Scholar 

  34. 34.

    Moskovitz DN, Van Assche G, Maenhout B, et al. (2006) Colectomy rates after cyclosporine induced remission: 7 years experience in ulcerative colitis. Clin Gastroenterol Hepatol 4: 760–765

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Van Assche G, D’Haens G, Noman M, et al. (2003) Randomized double blind comparison of 4 mg/kg vs 2 mg/kg ciclosporine in severe ulcerative colitis. Gastroenterology 125: 1025–1032

    PubMed  Article  Google Scholar 

  36. 36.

    De Saussure P, Soravia C, Morel P, Hadengue A (2005) Low dose oral microemulsion ciclosporine for severe refractory colitis. Alim Pharmacol Ther 22: 203–208

    Article  CAS  Google Scholar 

  37. 37.

    Weber A, Fein F, Koch S, et al. (2006) Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral®). Inflamm Bowel Dis 12: 1131–1135

    PubMed  Article  Google Scholar 

  38. 38.

    Sternhal M, George J, Kornbluth A, et al. (1996) Toxicity associated with the use of cyclosporine in patients with inflammatory bowel disease. Gastroenterology 110: A1019

    Google Scholar 

  39. 39.

    Arts J, D’Haens G, Zeegers M, et al. (2004) Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 10: 73–78

    PubMed  Article  Google Scholar 

  40. 40.

    Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ (2001) Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 4: 1436–1440

    Article  Google Scholar 

  41. 41.

    Domenech E, Garcia-Planella, Bernal I, et al. (2002) Azathioprine without oral cyclosporine in the long term maintenance of remission induced by intravenous cyclosporine in severe steroid-refractory ulcerative colitis. Alim Pharm Ther 16: 2061–2065

    Article  CAS  Google Scholar 

  42. 42.

    Kornbluth A, Present DH, Lichtiger S, Hanauer S (1997) Cyclosporine for severe ulcerative colitis: a user’s guide. Am J Gastroenterol 92: 1424–1428

    PubMed  CAS  Google Scholar 

  43. 43.

    Cacheux W, Lémann M, Marteau P, et al. (2006) Peut-on prédire la réponse à la ciclosporine dans les poussées graves de RCH corticorésistantes? Gastroentérol Clin Biol 30: A155

    Google Scholar 

  44. 44.

    Rowe FA, Walker JH, Karp LC, et al. (2000) Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 95: 2000–2008

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Rutgeerts P, Sandborn WJ, Feagan BG, et al. (2005) Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Probert CS, Hearing SD, Schreiber S, et al. (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52: 998–1002

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Gustavsson A, Järnerot G, Hertervig E, et al. (2007) A two year follow up of the Swedish-Danish infliximab/placebo trial in steroid resistant acute ulcerative coliitis. Gastroenterology 132: A146

    Google Scholar 

  48. 48.

    Lees CW, Heys D, Ho GT, et al. (2007) A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Alim Pharm Ther 26: 411–419

    CAS  Article  Google Scholar 

  49. 49.

    Kohn A, Daperno M, Armuzzi A, et al. (2007) Infliximab in severe ulcerative colitis: short term results of different infusion regimens and long temr follow up. Alim Pharm Ther 26: 747–756

    CAS  Article  Google Scholar 

  50. 50.

    Maser EA, Deconda D, Lichtiger S, et al. (2007) Cyclosporine A and infliximab as acute salvage therapy for each other in severe steroid refractory ulcerative colitis. Gastroenterology 132: A180

    Google Scholar 

  51. 51.

    Plevy S, Salzberg B, Van Assche G, et al. (2007) A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133: 1414–1422

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Van Assche G, Sandborn W, Feagan BG, et al. (2006) Daclizumab, a humanized monoclonal antibody to the interleukin 2 receptor (CD25) for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled dose ranging trial. Gut 55: 1568–1574

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Ogata H, Matsui T, Nakamura M, et al. (2006) A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55: 1255–1262

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Stremmel W, Ehehalt R, Autschbach F, Karner M (2007) Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 147: 603–610

    PubMed  Google Scholar 

  55. 55.

    Matsuoka K, Iwao Y, Mori T, et al. (2007) Cytomegalovirus Is Frequently Reactivated and Disappears Without Antiviral Agents in Ulcerative Colitis Patients. Am J Gastroenterol 102: 331–337

    PubMed  Article  Google Scholar 

  56. 56.

    de Saussure P, Lavergne-Slove A, Mazeron MC, et al. (2004) A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment Pharmacol Ther 20(11–12): 1323–1327

    PubMed  Article  Google Scholar 

  57. 57.

    Piton G, Dupont-Gossard AC, Weber A, et al. Cytomegalovirus infections in patients with steroid-refractory ulcerative colitis treated by oral microemulsion form of cyclosporine. Gastroentérol Clin Biol, sous presse

  58. 58.

    Rodemann JF, Dubberke ER, Reske KA, et al. (2007) Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 339–344

    PubMed  Article  Google Scholar 

  59. 59.

    Issa M, Vijayapal A, Graham MB, et al. (2007) Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5: 345–351

    PubMed  Article  Google Scholar 

  60. 60.

    Stenner JMC, White P, Gould SR, Lim AG (2001) Audit of a management of severe ulcerative colitis in a DGH. Gut 48(Suppl1): A87

    Google Scholar 

  61. 61.

    Ljung T, Karlen P, Schmidt D, et al. (2004) Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53: 849–853

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Dolwani S, Hawthorne AB (2003) Mortality caused by inflammatory bowel disease in the UK. A two year survey. Gut 52(Suppl 1): A 12

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to F. Carbonnel.

About this article

Cite this article

Carbonnel, F. Traitement médical de la RCH grave: lesquels et jusqu’où?. Colon Rectum 2, 10–16 (2008). https://doi.org/10.1007/s11725-008-0071-2

Download citation

Mots clés

  • Ciclosporine
  • Corticoïdes
  • Infliximab
  • Colectomie
  • Colite grave
  • Rectocolite hémorragique

Keywords

  • Cyclosporin
  • Steroid
  • Infliximab
  • Severe colitis
  • Ulcerative colitis